Results 131 to 140 of about 7,154 (184)

Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations. [PDF]

Proteins
Islam SM, Rahman MS, Singla S, Demissie R, Lee H.   +4 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 M^pro inhibitors. [PDF]

Sci Rep
Ibrahim MAA, Khaled DMA, Mahmoud DGM, Abdelrahman AHM, Sidhom PA, Han Y, Shoeib T, Aldahmash B, Rady A.   +8 more
europepmc   +1 more source

Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses [PDF]

Antiviral Research, 2023
Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main protease (Mpro), which is substantially conserved among different coronaviruses ...
Jiajing Li, Qiuwei Pan, Pengfei Li
exaly   +2 more sources